Issued Patents All Time
Showing 25 most recent of 41 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12130295 | NMR system and methods for multi-parameter metabolic vulnerability index evaluations | Irina Y. Shalaurova | 2024-10-29 |
| 11988679 | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter | Irina Y. Shalaurova | 2024-05-21 |
| 11990243 | Multiple-marker risk parameters predictive of conversion to diabetes | Irina Y. Shalaurova | 2024-05-21 |
| 11942187 | Methods, systems and computer programs for assessing CHD risk using adjusted HDL particle number measurements | — | 2024-03-26 |
| 11782002 | NMR quantification of TMAO | Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus +1 more | 2023-10-10 |
| 11710568 | Multi-parameter diabetes risk evaluations | Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier | 2023-07-25 |
| 11703501 | CHD risk stratification evaluations for subjects with high levels of large HDL-P | Irina Y. Shalaurova | 2023-07-18 |
| 11692995 | NMR measurements of NMR biomarker GlycA | Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore | 2023-07-04 |
| 11467171 | Methods and systems to detect and quantify the amount of LP-X and other abnormal lipoproteins in a biosample using NMR spectroscopy | Irina Y. Shalaurova, Alan T. Remaley, Maureen Sampson, Lita Freeman | 2022-10-11 |
| 11231429 | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter | Irina Y. Shalaurova | 2022-01-25 |
| 11156685 | NMR analyzers for clinical evaluation of biosamples | Elias J. Jeyarajah, Stephen Markham, Steven P. Matyus, David R. Morgan, Bruce D. Silberman +1 more | 2021-10-26 |
| 11156621 | Multi-parameter metabolic vulnerability index evaluations | Irina Y. Shalaurova | 2021-10-26 |
| 11124837 | Methods and systems for predicting colorectal cancer incidence and mortality | Sarnia Mora, Paulette Denise Chandler | 2021-09-21 |
| 11037683 | Multiple-marker risk parameters predictive of conversion to diabetes | Irina Y. Shalaurova | 2021-06-15 |
| 10852293 | NMR measurements of NMR biomarker GlycA | Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore | 2020-12-01 |
| 10613044 | NMR quantification of TMAO | Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus +1 more | 2020-04-07 |
| 10504610 | Methods, systems and computer programs for assessing CHD risk using adjusted HDL article number measurements | — | 2019-12-10 |
| 10386355 | CHD risk stratification evaluations for subjects with high levels of large HDL-P | Irina Y. Shalaurova | 2019-08-20 |
| 10388414 | Multi-parameter diabetes risk evaluations | Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier | 2019-08-20 |
| 10365339 | NMR analyzers for clinical evaluation of biosamples | Elias J. Jeyarajah, Stephen Markham, Steven P. Matyus, David R. Morgan, Bruce D. Silberman +1 more | 2019-07-30 |
| 9952232 | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter | Irina Y. Shalaurova | 2018-04-24 |
| 9928345 | Multiple-marker risk parameters predictive of conversion to diabetes | Irina Y. Shalaurova | 2018-03-27 |
| 9792410 | Multi-parameter diabetes risk evaluations | Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier | 2017-10-17 |
| 9541620 | NMR quantification of TMAO | Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus +1 more | 2017-01-10 |
| 9535144 | NMR quantification of TMAO | Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Stanley L. Hazan | 2017-01-03 |